Furthermore, molecular docking results indicated the stable binding connections between TQ/5-FU and the hub targets, i.e., MAP2K2, CASP3, PIK3CA, ESR1, CYP3A4, CYP2C19, and CYP2C9, suggesting that TQ, in combination with 5-FU, may treat colon cancer by modulating these hub targets. This evidence concerns the gene MAP2K2 and colonic neoplasm.